WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI - News) today reported financial results for the third quarter of 2007. The Company reported total revenues of $15.6 million in the third quarter of 2007, compared to $12.4 million in total revenues in the third quarter of 2006. These results reflect the Company’s acquisition of ANTARA® (fenofibrate) capsules in August 2006.
